时间标签：数据日期 2026-11-01 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31–2026/11/01 ｜ 情报发生日期 2026-11-01
研究问题
Introduction Osteoarthritis (OA) is among the most prevalent musculoskeletal disorders worldwide and represents a major cause of chronic pain, physical
方法
Statistical analysis All in vitro experiments were performed independently in triplicate, and five rats per group were included in the in vivo experiments.；Probe annotation was performed according to the GPL96 platform file; probes without gene symbols were removed, and duplicated gene symbols were processed to generate a gene-level expression matrix.；For GSK3B overexpression-based rescue experiments, ordinary two-way ANOVA was performed with MFPM1 treatment and GSK3B overexpression as two independent factors, followed by Šídák’s multiple-comparison test.
核心结论
MFPM1 treatment reversed these changes, as evidenced by a reduced NADP⁺/NADPH ratio, restored GSH/GSSG ratio, increased T-AOC, and decreased NO levels (Fig.；Collectively, these findings indicate that MFPM1 attenuated OA progression in vivo, as evidenced by reduced ROS deposition, improved knee joint function, alleviated cartilage degeneration, preserved matrix integrity, and restored ACAN and COL2A1 expression.；In contrast, the matrix-degrading enzymes ADAMTS5 and MMP13 were prominently increased under OA-like conditions but were significantly suppressed by MFPM1 (Fig.；AGE stimulation markedly disrupted cellular energy metabolism, as reflected by reduced ATP production and a decreased NAD⁺/NADH ratio (Fig.；Conclusion This study identifies mitochondrial dynamics remodeling as a critical mechanistic entry point for attenuating OA progression.
局限
Introduction Osteoarthritis (OA) is among the most prevalent musculoskeletal disorders worldwide and represents a major cause of chronic pain, physical limitation, and disability (Ansari et al. ).；In addition, the combined evidence from major organ histology, routine hematological analysis, and blood biochemical testing supports the preliminary in vivo safety of MFPM1 under the current experimental conditions.
对本项目的价值
临床前机制证据，需评估物种外推与剂量可行性：线粒体是衰老干预的共同下游效应器，可用于跨器官效应的统一读数。 ｜ 价值分 3.2/5（★★★☆☆）
全文来源
PubMed PMC JATS 全文（正文 77,118 字符，已过 DOI 逐字 + 题名指纹双重归属校验）
原文题录
- 英文标题：Mitochondrial remodeling with mitochondrial fusion promoter M1 for osteoarthritis therapy.
- 期刊与标识：Cell biology and toxicology · PMID 42957931 · DOI 10.1007/s10565-026-10242-8
B 级证据分级：B 级（同行评议临床前研究，主要为动物模型）
本文核心结论来自动物模型或体外细胞学，属临床前证据，不能外推至人体。「延长健康寿命」「改善功能」等表述在小鼠中的意义，与人类临床结局之间仍有距离。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。